<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Protein Expr Purif</journal-id>
      <journal-title-group>
        <journal-title>Protein Expression and Purification</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1046-5928</issn>
      <issn pub-type="epub">1096-0279</issn>
      <publisher>
        <publisher-name>Academic Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2837147</article-id>
      <article-id pub-id-type="pmid">19995609</article-id>
      <article-id pub-id-type="publisher-id">YPREP3628</article-id>
      <article-id pub-id-type="doi">10.1016/j.pep.2009.12.001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Streamlined, automated protocols for the production of milligram quantities of
         untagged recombinant human cyclophilin-A (hCypA) and untagged human proliferating cell
         nuclear antigen (hPCNA) using ÄKTAxpress™</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ludwig</surname>
            <given-names>Cornelia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wear</surname>
            <given-names>Martin A.</given-names>
          </name>
          <email>mwear@staffmail.ed.ac.uk</email>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Walkinshaw</surname>
            <given-names>Malcolm D.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>The Edinburgh Protein Production Facility (PPF), Centre for Translational and
               Chemical Biology (CTCB), Wellcome Centre for Cell Biology (WCCB), University of
               Edinburgh, Michael Swann Building, King’s Buildings, Mayfield Road, Edinburgh
               EH9 3JR, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author. <email>mwear@staffmail.ed.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>5</month>
        <year>2010</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2010</year>
      </pub-date>
      <volume>71</volume>
      <issue>1</issue>
      <fpage>54</fpage>
      <lpage>61</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>11</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2010 Elsevier Inc.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We developed streamlined, automated purification protocols for the
               production of milligram quantities of untagged recombinant human cyclophilin-A
               (hCypA) and untagged human proliferating cell nuclear antigen (hPCNA) from
                  <italic>Escherichia coli</italic>, using the ÄKTAxpress™
               chromatography system. The automated 2-step (cation exchange and size exclusion)
               purification protocol for untagged hCypA results in final purity and yields of
               ⩾93% and ∼5 mg L<sup>−1</sup>
               of original cell culture, respectively, in under 12 h, including
               all primary sample processing and column equilibration steps. The novel automated
               4-step (anion exchange, desalt, heparin-affinity and size exclusion, in linear
               sequence) purification protocol for untagged hPCNA results in final purity and yields
               of ⩾87% and ∼4 mg L<sup>−1</sup> of original cell culture, respectively, in under
                  24 h, including all primary sample processing and column
               equilibration steps. This saves in excess of four full working days when compared to
               the traditional protocol, producing protein with similar final yield, purity and
               activity. Furthermore, it limits a time-dependent protein aggregation, a problem with
               the traditional protocol that results in a loss of final yield. Both automated
               protocols were developed to use generic commercially available pre-packed columns and
               automatically prepared minimal buffers, designed to eliminate user and system
               variations, maximize run reproducibility, standardize yield and purity between
               batches, increase throughput and reduce user input to a minimum. Both protocols
               represent robust generic methods for the automated production of untagged hCypA and
               hPCNA.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Cyclophilin-A</kwd>
        <kwd>PCNA</kwd>
        <kwd>Automated protein purification</kwd>
        <kwd>Liquid chromatography</kwd>
        <kwd>ÄKTAXpress™</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>The demand placed on protein production strategies, in terms of the amount and
               purity of the protein products produced and the need to develop reliable and robust
               generic purification protocols, has increased massively in the post genome-sequencing
               era <xref rid="bib1" ref-type="bibr">[1]</xref>. This is especially so for the
               increasing pace and scope of structural genomics and drug discovery programs, where
               there is very often a need to generate tens of milligrams of highly pure protein on a
               regular basis, with as little batch variation as possible <xref rid="bib1 bib2 bib3 bib4 bib5" ref-type="bibr">[1–5]</xref>. Modern liquid
               chromatography instruments have become increasingly automated <xref rid="bib6 bib7 bib8" ref-type="bibr">[6–8]</xref> and associated separation media
               increasingly sophisticated <xref rid="bib9 bib10" ref-type="bibr">[9,10]</xref>,
               resulting in the development of effective methodologies for preparative protein
               purification, with increased throughput, becoming more and more routine <xref rid="bib1" ref-type="bibr">[1]</xref>. However, more often than not, these protocols are
               developed as bespoke methods for a particular protein or family of proteins, and make
               use of some very specific differences in biophysical properties particular to the
               individual protein(s). Although extremely effective, these bespoke methods do not
               translate particularly well into generic or high-throughput purification strategies.
               In addition to this, the vast majority of purification strategies involve more than
               one step (even for protocols utilizing some form of affinity enrichment as the first
               step <xref rid="bib11" ref-type="bibr">[11]</xref>) and most lab-scale
               chromatography instrumentation normally only handles a single chromatographic step at
               a time. As such, multistep purification protocols frequently involve time-consuming
               manual processing, including, for example, SDS–PAGE analysis of chromatograms
               and the subsequent pooling of the appropriate fractions, desalting or dialysis,
               concentration and application of the partially processed sample to the next
               chromatography column/step.</p>
      <p>The ÄKTAxpress™ liquid chromatography system (GE Healthcare) was the
               first widely available lab-scale system designed to specifically help address these
               demands, allowing preparative milligram-level protein purification protocols of up to
               4-steps to be automated and parallelized <xref rid="bib6" ref-type="bibr">[6]</xref>. A peak detection algorithm and a set of internal capillary
               loops allow peak fractions from intermediate steps to be collected automatically and
               processed through subsequent chromatography steps in the protocol. The system is able
               to process protein samples through a variety of affinity, ion-exchange, desalt and
               gel-filtration chromatography applications, using a set of generic pre-packed column
               types, with the option to include an on-column affinity tag removal cleavage step, as
               part of the protocol <xref rid="bib6" ref-type="bibr">[6]</xref>. One major
               advantage of this system is the non-modular design (apart from the columns and an
               external loop for the application of a protease, no other components are removed or
               added), which means each instrument is essentially operationally identical. All
               instruments have the same flow path delay volumes, the same gradient delay volumes,
               the same set of pre-defined column types and the same sets of limited user-editable
               protocol design parameters. This, in theory, means that there is no appreciable
               difference in way the instruments are run between laboratories, and translation of an
               already developed purification protocol from one instrument to another will not
               require any further system/user specific optimization that often plagues researchers
               trying to replicate a method using a different chromatography system to that used in
               a published protocol.</p>
      <p>The vast majority of protocols using the ÄKTAxpress™ utilize
               affinity chromatography as the first step <xref rid="bib6 bib12" ref-type="bibr">[6,12]</xref>, as this enrichment technique is easily scaled to fit the
               loop volume and sample handling restrictions of the instrument (the standard
               configuration has five 10 ml loops with a nominal 7.5 ml collection and process volume) for subsequent desalt or
               gel-filtration steps in the protocol. However, the presence of an affinity tag and
               optimizing its subsequent removal (very often a requirement for structural work)
               sometimes causes as many problems as the development of the purification protocol
               itself (even when utilizing the very widely exploited poly-histidine tag
                  <xref rid="bib11" ref-type="bibr">[11]</xref>). The small size and highly
               charged/polar nature of poly-histidine tags usually ensures that tagged-proteins
               structure and activity is rarely affected, but there are instances of this not being
               the case <xref rid="bib13 bib14" ref-type="bibr">[13,14]</xref>. Two proteins of
               particular interest to us as potential therapeutic targets – human
               cyclophilin-A (hCypA)<xref rid="fn1" ref-type="fn">1</xref> and human proliferating cell nuclear antigen
               (hPCNA) – have exhibited problems as tagged-proteins.</p>
      <p>Cyclophilins, found in all prokaryotes and eukaryotes and in all cellular
               compartments, are involved in protein assembly and cellular signaling <xref rid="bib15 bib16" ref-type="bibr">[15,16]</xref>. Their cellular function requires
               their peptidyl-prolyl isomerase (PPIase) activity that accelerates protein
               folding/unfolding <xref rid="bib17" ref-type="bibr">[17]</xref>. Most cyclophilins
               also bind the immunosuppressive drug cyclosporin-A (CsA) <xref rid="bib18" ref-type="bibr">[18]</xref>. In humans, the resulting hetero-dimeric complex inhibits
               calcineurin, blocking the signal transduction pathway to interleukin production
                  <xref rid="bib19 bib20" ref-type="bibr">[19,20]</xref>. Human cyclophilins
               have also recently become interesting drug targets in a number of diseases including
               HIV <xref rid="bib21 bib22" ref-type="bibr">[21,22]</xref> and HCV infection
                  <xref rid="bib23 bib24 bib25 bib26 bib27" ref-type="bibr">[23–27]</xref>, malaria <xref rid="bib28 bib29" ref-type="bibr">[28,29]</xref>, ischemia <xref rid="bib30 bib31 bib32" ref-type="bibr">[30–32]</xref>, immunosuppression, as well as showing potent
               anti-nematode effects <xref rid="bib16 bib33 bib34" ref-type="bibr">[16,33,34]</xref>.</p>
      <p>PNCA, an ubiquitous eukaryotic protein, is essential for DNA replication, DNA
               repair and plays major roles in the post-replicative processing of DNA <xref rid="bib35 bib36" ref-type="bibr">[35,36]</xref>. Functional PCNA is a toroidal trimer
               capable of encircling double-stranded DNA, enhancing polymerase processivity by
               tethering the polymerase complex to the target DNA <xref rid="bib37 bib38" ref-type="bibr">[37,38]</xref>. Many of the proteins that interact directly with PCNA
               are involved in the mechanics of DNA replication and repair <xref rid="bib37 bib38" ref-type="bibr">[37,38]</xref>. PCNA also interacts with proteins
               involved in post-replicative processing and with cell cycle regulatory proteins such
               as Gadd45 and p21 (WAF1/Cip1) <xref rid="bib35 bib39 bib40" ref-type="bibr">[35,39,40]</xref>. As a result of its central role in DNA replication
               and repair, PCNA has been highlighted <xref rid="bib41" ref-type="bibr">[41]</xref>
               as a potential therapeutic target in a multitude of proliferative cancers.</p>
      <p>Our laboratory has previously found that his-tags have adversely affected both
               the structure and function of cyclophilins and PCNA in a variety of activity and
               structural assays, as well as in a number of small molecule screening assays. In
               addition, tag cleavage has proved less than straightforward, for reasons undefined,
               and many of our small molecule screening assays and structural analyses require
               production of milligram amounts of very pure and active protein on a regular basis.
               As a direct result, we developed reliable and robust automated purification
               protocols, for the production of milligram amounts of very pure untagged recombinant
               human CypA, by easily adapting an existing protocol <xref rid="bib42" ref-type="bibr">[42]</xref>, and for untagged human PCNA, by development of a novel
               4-step protocol, using the ÄKTAxpress™ liquid chromatography system. Both
               automated protocols use generic commercially available pre-packed columns and
               automatically prepared minimal buffers, essentially eliminating user and system
               variations. They also maximize the run reproducibility and standardize the yield and
               purity between batches, increase throughput and reduce user input to a minimum. The
               automated 4-step protocol for hPCNA saves 4 working days over the traditional method,
               greatly increasing the overall productivity of the protocol. These two protocols
               further highlight the versatility of the ÄKTAxpress™ liquid chromatography
               as a way of standardizing lab-scale/process protein production.</p>
    </sec>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec sec-type="materials">
        <title>Materials</title>
        <p>All chemicals used were of the highest grade available
                  commercially.</p>
      </sec>
      <sec>
        <title>Plasmid construction</title>
        <p>Expression plasmids for recombinant hCypA (<italic>pSW3-001</italic>)
                  and hPCNA (<italic>pT7-PCNA</italic>) were constructed as described
                     <xref rid="bib42" ref-type="bibr">[42]</xref> and <xref rid="bib43" ref-type="bibr">[43]</xref>, respectively. <italic>pT7-PCNA</italic> was kindly
                  provided by Dr. Emma Warbrick (University of Dundee, UK).</p>
      </sec>
      <sec>
        <title>Protein expression and purification</title>
        <p>All purification was performed on ÄKTAxpress™ and
                  ÄKTA-Purifier 100 UPC (GE Healthcare) equipment at 6 °C. The ÄKTAxpress™ instruments were used in a standard
                  configuration with 10 ml collection loops. HiPrep 26/60 S-200 HR
                  gel-filtration and HiPrep 26/20 Desalt columns (GE Healthcare) were attached to
                  the system with the recommended lengths of 1.0 mm i.d.
                     Tefzel<sup>®</sup> tubing. All buffers, with the exception of
                     <italic>Buffer-H</italic>, were generated on an ÄKTA-Purifier 100
                  system fitted with an on-line <italic>Buffer Prep</italic> function, a
                     2 ml mixing chamber, using a flow rate of 30 ml min<sup>−1</sup> and the standard buffer
                  recipes (<xref rid="tbl1" ref-type="table">Table 1</xref>) supplied with the instrument software (UNICORN v 5.11, GE
                  Healthcare). Proteins were detected by absorbance at 280 nm.
                  Culture volumes used were 1L in all cases.</p>
      </sec>
      <sec>
        <title>Traditional purification of hCypA</title>
        <p>The following protocol was adapted from the method described by Wear et al.
                     <xref rid="bib42" ref-type="bibr">[42]</xref> to run with the appropriate
                  pre-packed column types for the ÄKTAxpress™ instrument and a minimal
                  buffer system. Recombinant hCypA was expressed and purified to homogeneity from
                  OverExpress C41 BL21(DE3) <italic>Escherichia coli</italic> (Lucigen)
                  transformed with the <italic>pSW3-001</italic> plasmid, grown shaking
                     (260 rpm) at 37 °C for 16 h in Overnight Express Instant TB Medium (Novagen) containing
                  carbenicillin (100 μg ml<sup>−1</sup>). Cells were harvested by centrifugation and
                  resuspended at 10% (w/v) in ice-cold <italic>Buffer-A</italic>
                     (<xref rid="tbl1" ref-type="table">Table 1</xref>), plus protease inhibitors.
                  Lysis was performed at 6 °C by a single passage through a
                  Constant Systems Cell Disruptor TS Series Benchtop instrument set to 22 kPSI.
                  Cellular debris was removed by centrifugation at 50,000<italic>g</italic>
                  for 1 h at 4 °C, and the filtered
                     (0.22 μm) supernatant was then applied to a 5 ml HiTrap SP HP column (GE Healthcare) pre-equilibrated in
                     <italic>Buffer-A</italic>, at 4 ml min<sup>−1</sup><italic>.</italic> The resin was washed
                  with 10 column volumes of <italic>Buffer-A</italic> at a flow rate of
                     4 ml min<sup>−1</sup> and bound
                  proteins were eluted with a gradient from 0% to 40%
                     <italic>Buffer-B</italic> over 10 column volumes (<xref rid="tbl1" ref-type="table">Table 1</xref>) at 4 ml min<sup>−1</sup>, collecting 2 ml fractions.
                  Relevant fractions (hCypA elutes between 13% and 22%
                     <italic>Buffer-B</italic>) were analysed using SDS–PAGE
                  (4–20% acrylamide), pooled (between 14% and 22%
                     <italic>Buffer-B</italic>) and the 10 ml sample flushed
                  from a 10 ml loop with one loop volume plus an additional
                     3 ml onto a HiPrep 26/60 S-200 HR gel-filtration column
                     (<italic>V</italic><sub>t</sub> ∼ 320 ml) (GE Healthcare) pre-equilibrated in
                     <italic>Buffer-C</italic> (<xref rid="tbl1" ref-type="table">Table
                     1</xref>). The column was run at 1.6 ml min<sup>−1</sup> and fraction collection was set to
                  start after 0.6 column volumes and continue for a further 0.2 column volumes,
                  collecting 2 ml fractions. Fractions containing hCypA (hCypA
                  peak <italic>V</italic><sub>e</sub> = 223.2 ml) were pooled, concentrated to
                     ∼500 μM and stored on ice. hCypA was ⩾93% pure as
                  judged by densitometric analysis of SDS–polyacrylamide gels.</p>
      </sec>
      <sec>
        <title>Automated purification of hCypA using
                  ÄKTAXpress™</title>
        <p>Recombinant hCypA was expressed and lysed as described above.
                     <italic>Buffer-A</italic>, <italic>Buffer-B</italic> and
                     <italic>Buffer-C</italic> (<xref rid="tbl1" ref-type="table">Table
                     1</xref>) and default system settings for a 2-step ion-exchange (IEX),
                  gel-filtration (GF) protocol, in the cold, were used unless otherwise stated.
                  Following lysis, the clarified supernatant was applied to an
                  ÄKTAXpress™ system fitted with a 5 ml HiTrap SP HP
                  column and a HiPrep 26/60 S-200 HR gel-filtration column. The IEX column was
                  eluted with a gradient from 0% to 40% <italic>Buffer-B</italic> over 10
                  column volumes. During elution of the IEX column, collection was set to
                  percentage, collecting between 15% and 21% <italic>Buffer-B</italic> into a
                  single loop. The peak detection parameters were left as default for level and
                  slope for the GF step, run in <italic>Buffer-C</italic> at 1.6 ml min<sup>−1</sup>, and fraction
                  collection was set to start after 0.6 column volumes and continue for a further
                  0.2 column volumes, collecting 2 ml fractions. Invariably,
                  fractions A7–B1 of the hCypA peak were pooled, concentrated to
                     ∼500 μM and stored on ice. hCypA was ⩾93% pure as
                  judged by densitometric analysis of SDS–polyacrylamide gels.</p>
      </sec>
      <sec>
        <title>Traditional purification of hPCNA</title>
        <p>OverExpress C43 BL21(DE3) <italic>E. coli</italic> (Lucigen)
                  transformed with the <italic>pT7-PCNA</italic> plasmid were grown shaking
                     (250 rpm) at 37 °C in LB media
                  containing carbenicillin (100 μg ml<sup>−1</sup>) until the
                     <italic>A</italic><sub>600</sub> was ∼0.7 and over-expression
                  of recombinant hPCNA was induced by addition of IPTG to 1 mM and
                  growth for a further 3 h at 37 °C. Cells
                  were harvested by centrifugation and resuspended at 10% (w/v) in ice-cold
                     <italic>Buffer-D</italic> (<xref rid="tbl1" ref-type="table">Table
                     1</xref>) plus protease inhibitors. Lysis was performed at 6 °C by a single passage through a Constant Systems Cell Disruptor
                  TS Series Benchtop instrument (Constant Systems) set to 25 kPSI. Cellular debris
                  was removed by centrifugation at 50,000<italic>g</italic> for 1 h at 4 °C, and the supernatant applied to a
                     5 ml HiTrap Q HP column (GE Healthcare) pre-equilibrated in
                     <italic>Buffer-D</italic>, at 5 ml min<sup>−1</sup>. Following loading, the column was washed with
                  15 column volumes 27% <italic>Buffer-E</italic> (<xref rid="tbl1" ref-type="table">Table 1</xref>), followed by a 2.7 column volume gradient from 27% to
                  54% <italic>Buffer-E</italic> and then a 5 column volume gradient from 54%
                  to 57% <italic>Buffer-E</italic>, at 5 ml min<sup>−1</sup>. Eluted protein was collected continuously in
                     1 ml fractions and analysed using SDS–PAGE (4–20%
                  acrylamide). Relevant fractions were pooled from 50.7% to 55.5%
                     <italic>Buffer-E</italic>. The protein pool (∼17 ml) was split into two equal aliquots and loaded onto a HiPrep 26/10 Desalting
                  column (GE Healthcare) pre-equilibrated in <italic>Buffer-F</italic>
                     (<xref rid="tbl1" ref-type="table">Table 1</xref>), run at 8 ml min<sup>−1</sup> and collecting 1 ml fractions. Relevant fractions containing protein were pooled and
                  loaded onto a 5 ml HiTrap Heparin HP column (GE Healthcare),
                  pre-equilibrated in <italic>Buffer-F</italic>, at 5 ml min<sup>−1</sup>. Following loading, the
                  resin was washed with 5 column volumes of 18% <italic>Buffer-G</italic>
                     (<xref rid="tbl1" ref-type="table">Table 1</xref>), followed by an 8.2 column
                  volume gradient from 18% to 100% <italic>Buffer-G</italic>, at 5 ml min<sup>−1</sup> collecting
                     2 ml fractions from 35.8% to 65.4%
                     <italic>Buffer-G</italic>. Eluted protein was analyzed by SDS–PAGE
                  (4–20% acrylamide) and relevant fractions pooled. The resulting 15 ml protein pool was then split into two equal 7.5 ml aliquots and loaded (7.5 ml sample flushed from a 10 ml loop with one loop volume plus an additional 3 ml) onto a HiPrep 26/60 Sephacryl S-200 HR gel-filtration column
                  pre-equilibrated with <italic>Buffer-H</italic> (<xref rid="tbl1" ref-type="table">Table 1</xref>), at 1.6 ml min<sup>−1</sup>. Relevant fractions containing hPCNA were
                  analyzed by SDS–PAGE, pooled from 110 to 128 ml,
                  concentrated to 100 μM and stored on ice. hPCNA was ⩾93%
                  pure as judged by densitometric analysis of SDS–polyacrylamide
                  gels.</p>
      </sec>
      <sec>
        <title>Automated purification of hPCNA using
                  ÄKTAXpress™</title>
        <p>Recombinant hPCNA was expressed and lysed as described above.
                     <italic>Buffer-D</italic>, <italic>Buffer-E</italic>,
                     <italic>Buffer-F</italic>, <italic>Buffer-G</italic> and
                     <italic>Buffer-H</italic> (<xref rid="tbl1" ref-type="table">Table
                     1</xref>) and default system settings for a 4-step ion-exchange (IEX),
                  desalt (DS), affinity (AF), gel-filtration (GF) protocol, in the cold, were used
                  unless otherwise stated. Following lysis, the clarified supernatant was applied to
                  an ÄKTAXpress™ system fitted with a 5 ml HiTrap Q HP
                  column, a HiPrep 26/10 Desalting column, a 5 ml HiTrap Heparin
                  HP column and a HiPrep 26/60 S-200 HR gel-filtration column. Following loading,
                  the 20 column volume <italic>wash-out-unbound-material</italic> parameter
                  was set to 0 and the column was washed with 15 column volumes 27%
                     <italic>Buffer-E</italic>, followed by a 2.7 column volume gradient from
                  27% to 54% <italic>Buffer-E</italic> and then a 5 column volume gradient
                  from 54% to 57% <italic>Buffer-E</italic>, at 5 ml min<sup>−1</sup>. During elution of the IEX column,
                  collection was set to percentage, starting at 50.6%
                     <italic>Buffer-E</italic> collecting 10 ml into a
                  single loop. During elution of the DS column with <italic>Buffer-F</italic>,
                  peak detection parameters were set to start at 80 mAU, with a
                  slope factor of 10 mAU min<sup>−1</sup>, a peak max of 0.15 and peak end of 50 mAU, with collection into two 10 ml loops. The
                  contents of both loops were loaded onto the AF column with a
                     <italic>peak-injection-flush-volume</italic> of 20 ml
                     <italic>Buffer-F</italic>. Following loading, the AF column was washed
                  with 5 column volumes of 18% <italic>Buffer-G</italic>, followed by an 8.2
                  column volume gradient from 18% to 100% <italic>Buffer-G</italic>. During
                  elution of the AF column with <italic>Buffer-G</italic>, collection was set
                  to percentage, starting at 39.7% <italic>Buffer-G</italic> collecting
                     10 ml into a single loop. The contents of the AF loop were
                  loaded onto the GF column with a
                     <italic>peak-injection-flush-volume</italic> of 13 ml.
                  During elution, peak detection parameters were left as default for level and
                  slope, with collection set to start after 0.26 column volumes and continue for a
                  further 0.21 CV, collecting 2 and 1 ml
                  fractions. Invariably, fractions A7–C11 of the hPCNA peak were pooled,
                  concentrated to ∼100 μM and stored on ice. hPCNA was
                  ⩾87% pure as judged by densitometric analysis of SDS–polyacrylamide
                  gels.</p>
      </sec>
      <sec>
        <title>Peptidyl-prolyl isomerase (PPIase) assay</title>
        <p>This colorimetric assay, performed essentially as described <xref rid="bib44 bib45" ref-type="bibr">[44,45]</xref>, determines the rate of the
                     <italic>cis</italic> to <italic>trans</italic> conversion of the
                  peptidyl-prolyl amide bond in the substrate
                     <italic>N</italic>-succinyl-Ala-Ala-Pro-Phe-<italic>p</italic>-nitroanilide
                  (sAAPF-pNA). Selective enzymatic hydrolysis of
                  sAA<italic>trans</italic>PF-pNA by α-chymotrypsin <xref rid="bib46" ref-type="bibr">[46]</xref> releases
                  <italic>p</italic>-ntitroaniline (pNA), the accumulation of which is
                  monitored by the absorbance at 400 nm. sAAPF-pNA, dissolved in
                     470 mM LiCl in 2,2,2-trifluroethanol (TFE) at 200 mM, was diluted to 4 mM in LiCl/TFE immediately
                  before use. Reactions were conducted at 6 °C in 50 mM HEPES, pH 8.0, 100 mM NaCl; 5 mM DTT, in a total reaction volume of 1 ml, essentially as
                  described <xref rid="bib44 bib45" ref-type="bibr">[44,45]</xref>. Final
                  concentrations of hCypA and AAPF-pNA were 15 and 100 μM,
                  respectively. The initial linear portion of the slopes (0–1.2 s) were converted to rates in μM s<sup>−1</sup> using the absorbance at 400 nm
                  and the extinction coefficient <italic>ε</italic><sub>400 nm</sub> = 10,050 M<sup>−1</sup>cm<sup>−1</sup>. The
                     IC<sub>50</sub> was determined by a least squares fit of Eq.
                     <xref rid="fd1" ref-type="disp-formula">(1)</xref> to plots of the initial reaction
                  rate (background thermal isomerisation rate subtracted),
                     <italic>V</italic><sub>o</sub> (in μM s<sup>−1</sup>), <italic>versus</italic> the concentration
                  of CsA.<disp-formula id="fd1"><label>(1)</label><alternatives><textual-form specific-use="jats-markup"><italic>V</italic><sub>o</sub> = <italic>V</italic><sub><italic>∞</italic></sub> + (<italic>V</italic><sub>zero</sub> - <italic>V</italic><sub><italic>∞</italic></sub>) / {(1 + ([CsA] / IC<sub>50</sub>)<sup><italic>Slope</italic></sup>)}</textual-form><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mtext>o</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mtext>zero</mml:mtext></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mtext>CsA</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mtext>IC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Slope</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math></alternatives></disp-formula><italic>V</italic><sub>∞</sub>
                  is the reaction rate at infinite inhibitor concentration (fixed at 0),
                     <italic>V</italic><sub>zero</sub> is the initial velocity in the
                  absence of inhibitor, [CsA] is the concentration of CsA, IC<sub>50</sub> is
                  the concentration of CypA that causes 50% inhibition and
                     <italic>Slope</italic> is the Hill number. Correction for substrate
                  competition was performed using Eq. <xref rid="fd2" ref-type="disp-formula">(2)</xref>.<disp-formula id="fd2"><label>(2)</label><alternatives><textual-form specific-use="jats-markup"><italic>K</italic><sub>ds</sub> = IC<sub>50</sub> / 1 + ([AAPF] / <italic>K</italic><sub>m</sub>)</textual-form><mml:math id="M2" altimg="si2.gif" overflow="scroll"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>ds</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>IC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mtext>AAPF</mml:mtext><mml:mo stretchy="false">]</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></alternatives></disp-formula>[AAPF]
                  is the initial AA<italic>cis</italic>PF-pNA concentration (mean = 51.6 μM) and
                     <italic>K</italic><sub>m</sub> is the substrate
                  Michaelis–Menten constant (798 ± 69 μM).</p>
      </sec>
      <sec>
        <title>Miscellaneous</title>
        <p>SDS–PAGE was performed as described <xref rid="bib47" ref-type="bibr">[47]</xref>. The molecular weights of hCypA, hPCNA and CsA are 18,012,
                  28,769 and 1202.12 Da, respectively. Protein concentration was
                  determined by measurement of absorbance at 280 nm and calculated
                  using the extinction coefficient 8490 M<sup>−1</sup> cm<sup>−1</sup>, for
                  hCypA and 16,305 M<sup>−1</sup> cm<sup>−1</sup>, for hPCNA, or by BCA protein assay (Pierce) with
                  bovine serum albumin (BSA) as a standard.</p>
      </sec>
    </sec>
    <sec>
      <title>Results and discussion</title>
      <sec>
        <title>hCypA</title>
        <p>Although the 2-step protocol (cation exchange and gel-filtration) for the
                  purification of untagged recombinant human CypA (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>A for typical soluble
                  expression levels of hCypA) described by Wear et al. <xref rid="bib42" ref-type="bibr">[42]</xref> generates very pure and active protein, there is still
                  significant manual intervention involved in processing the samples through to
                  purity. We streamlined the original <xref rid="bib42" ref-type="bibr">[42]</xref> traditional protocol (see Materials and methods for
                  details) by introducing several significant improvements. This was achieved
                  primarily by using generic pre-packed columns, a set of automatically generated
                  minimal buffers (<italic>Buffer-A</italic>, <italic>Buffer-B</italic>
                  and <italic>Buffer-C</italic>; <xref rid="tbl1" ref-type="table">Table
                     1</xref>), containing only buffer salt and NaCl, eliminating the need
                  for any additional components (except for the addition of a protease inhibitor
                  cocktail, added to the cell suspension mix just prior to high-pressure lysis), and
                  a significantly increased flow rate compared to the previous method (4 and
                     1 ml min<sup>−1</sup>,
                  respectively) <xref rid="bib42" ref-type="bibr">[42]</xref>. We switched the
                  cation exchange column of the first step to a generic commercially available
                  column type (a 5 ml HiTrap SP HP column; GE Healthcare), with a
                  greatly reduced bed volume (5 ml compared to the previous
                     ∼50 ml). This, coupled with the increased flow rate,
                  reduced the run time to less than 15% of the previous protocol (∼40 min compared to ∼300 min) <xref rid="bib42" ref-type="bibr">[42]</xref>. The loss of bed volume had no adverse effect
                  on the amount of sample we typically needed to process and the elution peak of
                  hCypA was, in general, between 7 and 8 ml in volume. Cell
                  extract from up to 3 l of original <italic>E.
                     coli</italic> culture could be similarly processed without any apparent loss
                  of purity or saturation of the dynamic binding capacity of the column
                     (∼40–60 mg protein ml<sup>−1</sup> of wet resin).hCypA invariably eluted
                  between 13% and 22% <italic>Buffer-B</italic> and, following SDS–PAGE
                  analysis, fractions collected between 14% and 22% <italic>Buffer-B</italic>
                  were pooled and processed over a HiPrep 26/60 S-200 HR gel-filtration column (GE
                  Healthcare), loading with a 10 ml loop with an additional
                     3 ml flush volume and run in <italic>Buffer-C</italic>
                     (<xref rid="tbl1" ref-type="table">Table 1</xref>). hCypA invariably eluted as
                  a symmetrical peak with an elution volume of 223.2 ± 0.3 ml (mean ± SD, <italic>n</italic> = 4). The streamlined traditional methodology was extremely
                  reproducible; <xref rid="fig1" ref-type="fig">Fig. 1</xref>C illustrates the
                  final protein obtained from 4 independent repeat runs. It routinely produced hCypA
                  with a final purity of ⩾93% and final yield of ∼5 mg per
                  litre of original bacterial culture (<xref rid="tbl2" ref-type="table">Table
                     2</xref>, <xref rid="fig1" ref-type="fig">Fig. 1</xref>C). The yields and purity we obtained with this method
                  were similar to those obtained using the previous method <xref rid="bib42" ref-type="bibr">[42]</xref>. However, the batch purity and yield
                  variability was significantly reduced and the total processing time (from cell
                  pellet to pure protein) was reduced by at least half.</p>
        <p>We next took the streamlined traditional protocol and translated it onto an
                  ÄKTAXpress™ system fitted with a 5 ml HiTrap SP HP
                  column and an HiPrep 26/60 S-200 HR gel-filtration column, with only a few minor
                  changes to the run parameters previously optimized for the traditional
                  methodology. Recombinant hCypA was expressed (<xref rid="fig1" ref-type="fig">Fig.
                     1</xref>A) and lysed identically to the traditional method.
                     <italic>Buffer-A</italic>, <italic>Buffer-B</italic> and
                     <italic>Buffer-C</italic> (generated automatically; <xref rid="tbl1" ref-type="table">Table 1</xref>) and default system settings for a 2-step
                  ion-exchange, gel-filtration protocol, in the cold, were used except for the
                  following changes. The ion-exchange column was eluted with a gradient from 0% to
                  40% <italic>Buffer-B</italic> over 10 column volumes, with collection set to
                  percentage, collecting between 15% and 21% <italic>Buffer-B</italic> into a
                  single loop. This sample was then processed onto the gel-filtration column run in
                     <italic>Buffer-C</italic>. Fraction collection was set to start after 0.6
                  column volumes and continue for a further 0.2 column volumes, collecting 2 ml fractions. <xref rid="fig1" ref-type="fig">Fig. 1</xref>B
                  illustrates the typical chromatogram obtained from such an automated run. The
                  inset shows the detail of the hCypA peak; the elution volume for hCypA was
                     222.9 ± 0.12 ml
                     (mean ± SD,
                     <italic>n</italic> = 3), essentially
                  identical to the traditional method, and the fractions finally pooled from these
                  runs were invariably A7–B1 (<xref rid="fig1" ref-type="fig">Fig.
                  1</xref>B). Analysis of the final pool of protein indicated hCypA was
                  ⩾93% pure (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C), with
                  independent repeat runs of the automatic method producing protein with essentially
                  identical purity and yield (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C,
                     <xref rid="tbl2" ref-type="table">Table 2</xref>), illustrating the excellent
                  reproducibility of the automated protocol. Furthermore, the specific activity of
                  purified hCypA is very high; <xref rid="fig1" ref-type="fig">Fig. 1</xref>D
                  shows a comparison of the PPIase activity of protein purified either by the
                  traditional method or the automated methods. The values for the equilibrium
                  dissociation constant for CsA inhibition
                     (<italic>K</italic><sub>i</sub>) are 24.3 ± 4.2 nM, for traditionally
                  purified hCypA, and 19.7 ± 2.8 nM, for automatically purified hCypA, agreeing very well with
                  literature values <xref rid="bib42 bib44 bib48" ref-type="bibr">[42,44,48]</xref>.</p>
        <p>Due to the ability to pool more judiciously and manually process the sample
                  between columns with the traditional method, the final yields of hCypA generated
                  were typically ∼5–7% higher than the automated method; yields were
                     ∼5 mg per litre of original culture (<xref rid="tbl2" ref-type="table">Table 2</xref>). However, the automated 2-step
                  purification protocol involves very much less user intervention and the processing
                  time from cell pellet to final pure protein is less than 12 h,
                  including all primary sample processing and column equilibration steps. This saves
                  almost half a working day of user intervention over the traditional method making
                  the automatic method far more efficient. Despite this small loss of yield compared
                  to the traditional protocol, our automated purification protocol for untagged
                  recombinant hCypA using the ÄKTAXpress™ system represents a very rapid,
                  robust, reproducible and, most importantly, an improved generic methodology for
                  the production of milligram quantities of very pure protein.</p>
      </sec>
      <sec>
        <title>hPCNA</title>
        <p>Novel protocols for the purification of recombinant untagged hPCNA from
                     <italic>E. coli</italic> were developed from scratch (see Materials and
                  Methods for full details). We first developed a traditional 4-step ion-exchange
                  (IEX), desalt (DS), affinity (AF), gel-filtration (GF) methodology, again
                  utilizing generic pre-packed columns (suitable for use on the
                  ÄKTAXpress™ system), and a set of automatically generated minimal
                  buffers (<italic>Buffer-D</italic>, <italic>Buffer-E</italic>,
                     <italic>Buffer-F</italic>, <italic>Buffer-G</italic>, <xref rid="tbl1" ref-type="table">Table 1</xref>; <xref rid="fig2" ref-type="fig">Fig.
                     2</xref>). The IEX column elution uses a
                  relatively complex 4-step gradient profile: a wash immediately following sample
                  application with 15 column volumes of 27% <italic>Buffer-E</italic>,
                  followed by a 2.7 column volume gradient from 27% to 54%
                     <italic>Buffer-E</italic>, followed by a 5 column volume gradient from
                  54% to 57% <italic>Buffer-E</italic>, followed by a step to 100%
                     <italic>Buffer-E</italic>. Relevant hPCNA fractions from 50.7% to 55.5%
                     <italic>Buffer-E</italic> were pooled and further processed. This
                  gradient profile proved critical for ensuring hPCNA eluted with as narrow an
                  elution peak as possible (between 16 and 17 ml), while at the
                  same time limiting the level and number of contaminants, allowing an easy 2-repeat
                  run processing through the subsequent desalting step without further
                  concentration. hPCNA purified by this method was ⩾93% pure as judged by
                  densitometric analysis of SDS–polyacrylamide gels (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B) and typically yielded ∼2.5 mg per litre of original bacterial culture (<xref rid="tbl2" ref-type="table">Table 2</xref>). Despite the fact that very pure protein
                  could be reproducibly obtained (<xref rid="fig2" ref-type="fig">Fig.
                  2</xref>B), the traditional method requires a very considerable amount of
                  manual intervention and typically takes 5 full working days to process the protein
                  from cell pellet through to purity. Furthermore, a significant amount of protein
                     (∼1–2 mg) was lost over the course of purification
                  due to a time-dependent aggregation and resulting precipitation problems. These
                  effects were only partially alleviated by the addition of glycerol to the
                  chromatography buffers. Thus, in an attempt to reduce the loss of protein, to
                  greatly reduce the amount of user input to a minimum and to further standardize
                  the purification, we streamlined this method further by translating it into a
                  fully automated protocol on the ÄKTAXpress™ system.</p>
        <p>Clarified <italic>E. coli</italic> cell lysate containing recombinant
                  hPCNA was applied to an ÄKTAXpress™ system fitted with a 5 ml HiTrap Q HP column (GE Healthcare), a HiPrep 26/10 Desalting
                  column (GE Healthcare), a 5 ml HiTrap Heparin HP column (GE
                  Healthcare) and a HiPrep 26/60 S-200 HR gel-filtration column (GE Healthcare).
                     <italic>Buffer-D</italic>, <italic>Buffer-E</italic>,
                     <italic>Buffer-F</italic>, <italic>Buffer-G</italic> (generated
                  automatically; <xref rid="tbl1" ref-type="table">Table 1</xref>) and
                     <italic>Buffer-H</italic> (<xref rid="tbl1" ref-type="table">Table
                     1</xref>), and default system settings for a 4-step ion-exchange,
                  desalting, affinity, gel-filtration protocol, in the cold, were used except for
                  the following changes (see Materials and methods for full details). Following
                  loading, column was washed with 15 column volumes 27%
                     <italic>Buffer-E</italic> (setting the default
                     <italic>wash-out-unbound-material</italic> parameter to 0), followed by a
                  2.7 column volume gradient from 27% to 54% <italic>Buffer-E</italic> and
                  then a 5 column volume gradient from 54% to 57% <italic>Buffer-E</italic>,
                  followed by a step to 100% <italic>Buffer-E</italic> at 5 ml min<sup>−1</sup> (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). During elution of the IEX column, collection was set
                  to percentage, starting at 50.6% <italic>Buffer-E</italic>, collecting
                     10 ml (instead of the default 7.5 ml) into
                  a single loop; the protein was further processed through a desalting step. During
                  elution of the DS column with <italic>Buffer-F</italic>, peak detection
                  parameters were set to start at 80 mAU, with a slope factor of
                     10 mAU min<sup>−1</sup>, a peak
                  max of 0.15 and peak end of 50 mAU, with collection into two
                     10 ml loops. The contents of both loops were loaded onto a
                     5 ml Heparin AF column with a
                     <italic>peak-injection-flush-volume</italic> of 20 ml
                     <italic>Buffer-F</italic>. Following loading, the AF column was washed
                  with 5 column volumes of 18% Buffer-<italic>G</italic>, followed by elution
                  with an 8.2 column volume gradient from 18% to 100%
                     <italic>Buffer-G</italic>. During elution of the AF column with
                     <italic>Buffer-G</italic> collection was set to percentage, starting at
                  39.7% <italic>Buffer-G</italic>, collecting 10 ml, again
                  into a single loop. We found the minor loss of sample arising from using the
                  entire loop volume, due to laminar flow where velocity increases as the center of
                  the tube is approached, was more than compensated by the increased yield that
                  resulted from collecting 10 ml of sample through the core of the
                  eluted protein peak for both the IEX and AF columns. The contents of the entire AF
                  loop were then loaded onto the GF column with the default
                     <italic>peak-injection-flush-volume</italic> of 13 ml.
                  During elution peak detection, parameters were left as default for level and slope
                  with collection set to start after 0.26 column volumes and continue for a further
                  for 0.21 CV, collecting 2 and 1 ml fractions
                     (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). Fractions, invariably
                  A7–C11, of the hPCNA peak were pooled, concentrated to ∼100 μM and stored on ice. hPCNA was ⩾87% pure as judged by
                  densitometric analysis of SDS–polyacrylamide gels (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B, <xref rid="tbl2" ref-type="table">Table
                     2</xref>).</p>
        <p>Independent repeat runs of the fully automated method produced protein with
                  the same degree of high purity (<xref rid="fig2" ref-type="fig">Fig.
                  2</xref>B), illustrating the excellent reproducibility of the automated
                  protocol. Streamlining and translation of the purification protocol onto an
                  ÄKTAXpress™ system reduces the processing time to a fraction of that
                  taken by the traditional method. The automated run takes less than 24 h, including all primary processing and column equilibration steps,
                  with minimal user input to process the sample through from cell pellet to final
                  purity, compared to the 5 full working days of the traditional methodology. This
                  is particularly important; hPCNA is prone to time-dependent aggregation and the
                  automated protocol limits the loss of protein to this effect. As a direct result,
                  the final yield of protein from a litre of original culture obtained from the
                  automated method was typically ∼40% greater than the traditional method
                     (3.6 mg <italic>versus</italic> 2.5 mg; <xref rid="fig2" ref-type="fig">Fig. 2</xref>B, <xref rid="tbl2" ref-type="table">Table 2</xref>), purely as a result of being able to
                  process and purify the protein very much more quickly. Our automated purification
                  protocol for untagged recombinant hPCNA using the ÄKTAXpress™ system
                  represents a novel generic methodology for the production of milligram quantities
                  of pure protein.</p>
      </sec>
      <sec>
        <title>Concluding remarks</title>
        <p>We have developed reliable and robust automated purification protocols, for
                  the production of milligram amounts of very pure untagged recombinant human CypA,
                  by easily adapting an existing protocol <xref rid="bib42" ref-type="bibr">[42]</xref>, and for untagged human PCNA, by development of a novel
                  4-step protocol, using the ÄKTAxpress™ liquid chromatography system.
                  Both automated protocols use generic commercially available pre-packed columns and
                  automatically prepared minimal buffers (essentially eliminating user error and
                  system variations), helping to further maximize run reproducibility and
                  standardize the yield and purity between batches. They also increase throughput
                  and reduce user input to a minimum; the automated 4-step protocol for hPCNA saves
                  4 working days over the traditional method increasing the overall productivity of
                  the protocol. These two protocols also further highlight the versatility and high
                  degree of reproducibility of the ÄKTAxpress™ liquid chromatography
                  system as a lab-scale production system.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Fulghum</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Austen</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Swalley</surname>
              <given-names>S.E.</given-names>
            </name>
          </person-group>
          <article-title>E. Coli and insect cell expression, automated purification and
                           quantitative analysis</article-title>
          <source>Methods Mol. Biol.</source>
          <volume>498</volume>
          <year>2009</year>
          <fpage>143</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">18988024</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hiraki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Nagai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ihara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kudo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nagae</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Uejima</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Oda</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chavas</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Matsugaki</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wakatsuki</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Development of an automated large-scale
                           protein-crystallization and monitoring system for high-throughput
                           protein-structure analyses</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>62</volume>
          <year>2006</year>
          <fpage>1058</fpage>
          <lpage>1065</lpage>
          <pub-id pub-id-type="pmid">16929107</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alzari</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Berglund</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Berrow</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Blagova</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Busso</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Campanacci</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Christodoulou</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Eiler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fogg</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Folkers</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Geerlof</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Haouz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Macieira</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nordlund</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Perrakis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Quevillon-Cheruel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tarandeau</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>van Tilbeurgh</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Luna-Vargas</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Velarde</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Willmanns</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Implementation of semi-automated cloning and prokaryotic
                           expression screening: the impact of SPINE</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>62</volume>
          <year>2006</year>
          <fpage>1103</fpage>
          <lpage>1113</lpage>
          <pub-id pub-id-type="pmid">17001088</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Au</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Berrow</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Blagova</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Boucher</surname>
              <given-names>I.W.</given-names>
            </name>
            <name>
              <surname>Boyle</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Brannigan</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>L.G.</given-names>
            </name>
            <name>
              <surname>Dierks</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Folkers</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Grenha</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Harlos</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kaptein</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kalliomaa</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Levdikov</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Milioti</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Moroz</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Rzechorzek</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Sainsbury</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Stuart</surname>
              <given-names>D.I.</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>T.S.</given-names>
            </name>
            <name>
              <surname>Waterman</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Zaccai</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Esnouf</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Fogg</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Application of high-throughput technologies to a structural
                           proteomics-type analysis of Bacillus anthracis</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>62</volume>
          <year>2006</year>
          <fpage>1267</fpage>
          <lpage>1275</lpage>
          <pub-id pub-id-type="pmid">17001104</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berrow</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Bussow</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Coutard</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Diprose</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ekberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Folkers</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lieu</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Peleg</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Pinaglia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Quevillon-Cheruel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Salim</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Scheich</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Vincentelli</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Busso</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant protein expression and solubility screening in
                              <italic>Escherichia coli</italic>: a comparative
                           study</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>62</volume>
          <year>2006</year>
          <fpage>1218</fpage>
          <lpage>1226</lpage>
          <pub-id pub-id-type="pmid">17001098</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhikhabhai</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sjöberg</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hedkvist</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Galin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Liljedahl</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Frigård</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Pettersson</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sigrell-Simon</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Markeland-Johansson</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Production of milligram quantities of affinity tagged-proteins
                           using automated multistep chromatographic purification</article-title>
          <source>J. Chromatogr. A</source>
          <volume>1080</volume>
          <year>2005</year>
          <fpage>83</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">16013618</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stromberg</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rotticci-Mulder</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bjornestedt</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Preparative parallel protein purification (P4)</article-title>
          <source>J. Chromatogr. B Analyt. Technol. Biomed. Life
                                 Sci.</source>
          <volume>818</volume>
          <year>2005</year>
          <fpage>11</fpage>
          <lpage>18</lpage>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riek</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wallimann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schlattner</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>A versatile multidimensional protein purification system with
                           full Internet remote control based on a standard HPLC
                           system</article-title>
          <source>Biotechniques</source>
          <volume>46</volume>
          <year>2009</year>
          <fpage>ix</fpage>
          <lpage>xii</lpage>
          <pub-id pub-id-type="pmid">19480643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakamoto</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kabe</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hatakeyama</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Handa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Development and application of high-performance affinity
                           beads: toward chemical biology and drug discovery</article-title>
          <source>Chem. Rec.</source>
          <volume>9</volume>
          <year>2009</year>
          <fpage>66</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">19243077</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>J.X.</given-names>
            </name>
            <name>
              <surname>Tressel</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Seewoester</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Implementation of advanced technologies in commercial
                           monoclonal antibody production</article-title>
          <source>Biotechnol. J.</source>
          <volume>3</volume>
          <year>2008</year>
          <fpage>1185</fpage>
          <lpage>1200</lpage>
          <pub-id pub-id-type="pmid">18759247</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waugh</surname>
              <given-names>D.S.</given-names>
            </name>
          </person-group>
          <article-title>Making the most of affinity tags</article-title>
          <source>Trends Biotechnol.</source>
          <volume>23</volume>
          <year>2005</year>
          <fpage>316</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">15922084</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Naismith</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <article-title>A simple and efficient expression and purification system
                           using two newly constructed vectors</article-title>
          <source>Protein Expr. Purif.</source>
          <volume>63</volume>
          <year>2009</year>
          <fpage>102</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="pmid">18845260</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Filutowicz</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Hexahistidine (His6)-tag dependent protein dimerization: a
                           cautionary tale</article-title>
          <source>Acta Biochim. Pol.</source>
          <volume>46</volume>
          <year>1999</year>
          <fpage>591</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">10698267</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wear</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>A kinetically trapped intermediate of FK506 binding protein
                           forms in vitro: chaperone machinery dominates protein folding in
                           vivo</article-title>
          <source>Protein Expr. Purif.</source>
          <volume>51</volume>
          <year>2007</year>
          <fpage>80</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">16908189</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Galat</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Peptidyl prolyl cis/trans isomerases (immunophilins):
                           biological diversity – targets – functions</article-title>
          <source>Curr. Top. Med. Chem.</source>
          <volume>3</volume>
          <year>2003</year>
          <fpage>1315</fpage>
          <lpage>1347</lpage>
          <pub-id pub-id-type="pmid">12871165</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Page</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>MacNiven</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hengartner</surname>
              <given-names>M.O.</given-names>
            </name>
          </person-group>
          <article-title>Cloning and biochemical characterization of the cyclophilin
                           homologues from the free-living nematode <italic>Caenorhabditis
                              elegans</italic></article-title>
          <source>Biochem. J.</source>
          <volume>317</volume>
          <issue>Pt. 1</issue>
          <year>1996</year>
          <fpage>179</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">8694762</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fanghanel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Insights into the catalytic mechanism of peptidyl prolyl
                           cis/trans isomerases</article-title>
          <source>Front. Biosci.</source>
          <volume>9</volume>
          <year>2004</year>
          <fpage>3453</fpage>
          <lpage>3478</lpage>
          <pub-id pub-id-type="pmid">15353370</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Handschumacher</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Harding</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Drugge</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Speicher</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Cyclophilin: a specific cytosolic binding protein for
                           cyclosporin A</article-title>
          <source>Science</source>
          <volume>226</volume>
          <year>1984</year>
          <fpage>544</fpage>
          <lpage>547</lpage>
          <pub-id pub-id-type="pmid">6238408</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Farmer</surname>
              <given-names>J.D.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>W.S.</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Weissman</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <article-title>Calcineurin is a common target of
                           cyclophilin–cyclosporin A and FKBP-FK506 complexes</article-title>
          <source>Cell</source>
          <volume>66</volume>
          <year>1991</year>
          <fpage>807</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="pmid">1715244</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rovira</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mascarell</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Truffa-Bachi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>The impact of immunosuppressive drugs on the analysis of T
                           cell activation</article-title>
          <source>Curr. Med. Chem.</source>
          <volume>7</volume>
          <year>2000</year>
          <fpage>673</fpage>
          <lpage>692</lpage>
          <pub-id pub-id-type="pmid">10702633</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Methot</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tremblay</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Plunder and stowaways: incorporation of cellular proteins by
                           enveloped viruses</article-title>
          <source>J. Virol.</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>6577</fpage>
          <lpage>6587</lpage>
          <pub-id pub-id-type="pmid">15890896</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guichou</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Viaud</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mettling</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Subra</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Y.L.</given-names>
            </name>
            <name>
              <surname>Chavanieu</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Structure-based design, synthesis, and biological evaluation
                           of novel inhibitors of human cyclophilin A</article-title>
          <source>J. Med. Chem.</source>
          <volume>49</volume>
          <year>2006</year>
          <fpage>900</fpage>
          <lpage>910</lpage>
          <pub-id pub-id-type="pmid">16451056</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watashi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hijikata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Miyanari</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Shimotohno</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Cyclophilin B is a functional regulator of hepatitis C virus
                           RNA polymerase</article-title>
          <source>Mol. Cell</source>
          <volume>19</volume>
          <year>2005</year>
          <fpage>111</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="pmid">15989969</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watashi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shimotohno</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Current approaches for developing new anti-HCV agents and
                           analyses of HCV replication using anti-HCV agents</article-title>
          <source>Uirusu</source>
          <volume>55</volume>
          <year>2005</year>
          <fpage>105</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">16308536</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bobardt</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>de Witte</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Selvarajah</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chatterji</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Sanders-Beer</surname>
              <given-names>B.E.</given-names>
            </name>
            <name>
              <surname>Geijtenbeek</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Chisari</surname>
              <given-names>F.V.</given-names>
            </name>
            <name>
              <surname>Gallay</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Hepatitis C virus NS5A anchor peptide disrupts human
                           immunodeficiency virus</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>105</volume>
          <year>2008</year>
          <fpage>5525</fpage>
          <lpage>5530</lpage>
          <pub-id pub-id-type="pmid">18378908</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flisiak</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Horban</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gallay</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bobardt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Selvarajah</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wiercinska-Drapalo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Siwak</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Cielniak</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Higersberger</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kierkus</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Aeschlimann</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Grosgurin</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Nicolas-Metral</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Dumont</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Porchet</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Crabbe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Scalfaro</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>The cyclophilin inhibitor Debio-025 shows potent
                           anti-hepatitis C effect in patients coinfected with hepatitis C and human
                           immunodeficiency virus</article-title>
          <source>Hepatology</source>
          <volume>47</volume>
          <year>2008</year>
          <fpage>817</fpage>
          <lpage>826</lpage>
          <pub-id pub-id-type="pmid">18302285</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chatterji</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Bobardt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Selvarajah</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Vuagniaux</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Parkinson</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gallay</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>The isomerase active site of cyclophilin a is critical for HCV
                           replication</article-title>
          <source>J. Biol. Chem.</source>
          <volume>284</volume>
          <issue>25</issue>
          <year>2009</year>
          <fpage>16998</fpage>
          <lpage>17005</lpage>
          <pub-id pub-id-type="pmid">19380579</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bell</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wernli</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>R.M.</given-names>
            </name>
          </person-group>
          <article-title>Roles of peptidyl-prolyl cis-trans isomerase and calcineurin
                           in the mechanisms of antimalarial action of cyclosporin A, FK506, and
                           rapamycin</article-title>
          <source>Biochem. Pharmacol.</source>
          <volume>48</volume>
          <year>1994</year>
          <fpage>495</fpage>
          <lpage>503</lpage>
          <pub-id pub-id-type="pmid">7520696</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gavigan</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Kiely</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Hirtzlin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Cyclosporin-binding proteins of <italic>Plasmodium
                              falciparum</italic></article-title>
          <source>Int. J. Parasitol.</source>
          <volume>33</volume>
          <year>2003</year>
          <fpage>987</fpage>
          <lpage>996</lpage>
          <pub-id pub-id-type="pmid">12906882</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crompton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Virji</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Cyclophilin-D binds strongly to complexes of the
                           voltage-dependent anion channel and the adenine nucleotide translocase to
                           form the permeability transition pore</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>258</volume>
          <year>1998</year>
          <fpage>729</fpage>
          <lpage>735</lpage>
          <pub-id pub-id-type="pmid">9874241</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waldmeier</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tintelnot-Blomley</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lemasters</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>Cyclophilin D as a drug target</article-title>
          <source>Curr. Med. Chem.</source>
          <volume>10</volume>
          <year>2003</year>
          <fpage>1485</fpage>
          <lpage>1506</lpage>
          <pub-id pub-id-type="pmid">12871122</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baines</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Purcell</surname>
              <given-names>N.H.</given-names>
            </name>
            <name>
              <surname>Blair</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Osinska</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hambleton</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Brunskill</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Sayen</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Dorn</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Molkentin</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Loss of cyclophilin D reveals a critical role for
                           mitochondrial permeability transition in cell death</article-title>
          <source>Nature</source>
          <volume>434</volume>
          <year>2005</year>
          <fpage>658</fpage>
          <lpage>662</lpage>
          <pub-id pub-id-type="pmid">15800627</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Page</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Carlow</surname>
              <given-names>C.K.</given-names>
            </name>
          </person-group>
          <article-title>Parasite cyclophilins and antiparasite activity of cyclosporin
                           A</article-title>
          <source>Parasitol. Today</source>
          <volume>11</volume>
          <year>1995</year>
          <fpage>385</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">15275401</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Moir</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kontopidis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wear</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Malone</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Structure-based discovery of a family of synthetic cyclophilin
                           inhibitors showing a cyclosporin-A phenotype in <italic>C.
                              elegans</italic></article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>363</volume>
          <issue>4</issue>
          <year>2007</year>
          <fpage>1013</fpage>
          <lpage>1019</lpage>
          <pub-id pub-id-type="pmid">17927958</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moldovan</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Pfander</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Jentsch</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>PCNA, the maestro of the replication fork</article-title>
          <source>Cell</source>
          <volume>129</volume>
          <year>2007</year>
          <fpage>665</fpage>
          <lpage>679</lpage>
          <pub-id pub-id-type="pmid">17512402</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warbrick</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>A functional analysis of PCNA-binding peptides derived from
                           protein sequence, interaction screening and rational
                           design</article-title>
          <source>Oncogene</source>
          <volume>25</volume>
          <year>2006</year>
          <fpage>2850</fpage>
          <lpage>2859</lpage>
          <pub-id pub-id-type="pmid">16407840</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelman</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hurwitz</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Protein–PCNA interactions: a DNA-scanning
                           mechanism?</article-title>
          <source>Trends Biochem. Sci.</source>
          <volume>23</volume>
          <year>1998</year>
          <fpage>236</fpage>
          <lpage>238</lpage>
          <pub-id pub-id-type="pmid">9697409</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelman</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hurwitz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>O’Donnell</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Processivity of DNA polymerases: two mechanisms, one
                           goal</article-title>
          <source>Structure</source>
          <volume>6</volume>
          <year>1998</year>
          <fpage>121</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="pmid">9519403</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warbrick</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Glover</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>L.S.</given-names>
            </name>
          </person-group>
          <article-title>A small peptide inhibitor of DNA replication defines the site
                           of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and
                           proliferating cell nuclear antigen</article-title>
          <source>Curr. Biol.</source>
          <volume>5</volume>
          <year>1995</year>
          <fpage>275</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="pmid">7780738</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hall</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Kearsey</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Coates</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Norman</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Warbrick</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>L.S.</given-names>
            </name>
          </person-group>
          <article-title>Characterisation of the interaction between PCNA and
                           Gadd45</article-title>
          <source>Oncogene</source>
          <volume>10</volume>
          <year>1995</year>
          <fpage>2427</fpage>
          <lpage>2433</lpage>
          <pub-id pub-id-type="pmid">7784094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kontopidis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>S.Y.</given-names>
            </name>
            <name>
              <surname>Zheleva</surname>
              <given-names>D.I.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Structural and biochemical studies of human proliferating cell
                           nuclear antigen complexes provide a rationale for cyclin association and
                           inhibitor design</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>102</volume>
          <year>2005</year>
          <fpage>1871</fpage>
          <lpage>1876</lpage>
          <pub-id pub-id-type="pmid">15681588</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wear</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Malone</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dunsmore</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>A surface plasmon resonance-based assay for small molecule
                           inhibitors of human cyclophilin A</article-title>
          <source>Anal. Biochem.</source>
          <volume>345</volume>
          <year>2005</year>
          <fpage>214</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">16102717</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fien</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Stillman</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Identification of replication factor C from
                              <italic>Saccharomyces cerevisiae</italic>: a component of the
                           leading-strand DNA replication complex</article-title>
          <source>Mol. Cell. Biol.</source>
          <volume>12</volume>
          <year>1992</year>
          <fpage>155</fpage>
          <lpage>163</lpage>
          <pub-id pub-id-type="pmid">1346062</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kofron</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Kuzmic</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kishore</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Colon-Bonilla</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Determination of kinetic constants for peptidyl prolyl
                           cis-trans isomerases by an improved spectrophotometric
                           assay</article-title>
          <source>Biochemistry</source>
          <volume>30</volume>
          <year>1991</year>
          <fpage>6127</fpage>
          <lpage>6134</lpage>
          <pub-id pub-id-type="pmid">2059621</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wear</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Kan</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rabu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Experimental determination of van der waals energies in a
                           biological system</article-title>
          <source>Angew. Chem. Int. Ed. Engl.</source>
          <volume>46</volume>
          <year>2007</year>
          <fpage>6453</fpage>
          <lpage>6456</lpage>
          <pub-id pub-id-type="pmid">17654646</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schellenberger</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Conformational specificity of chymotrypsin toward
                           proline-containing substrates</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>791</volume>
          <year>1984</year>
          <fpage>87</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">6498206</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laemmli</surname>
              <given-names>U.K.</given-names>
            </name>
          </person-group>
          <article-title>Cleavage of structural proteins during the assembly of the
                           head of bacteriophage T4</article-title>
          <source>Nature</source>
          <volume>227</volume>
          <year>1970</year>
          <fpage>680</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">5432063</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wear</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Walkinshaw</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Thermodynamics of the cyclophilin-A/cyclosporin-A interaction:
                           a direct comparison of parameters determined by surface plasmon resonance
                           using Biacore T100 and isothermal titration calorimetry</article-title>
          <source>Anal. Biochem.</source>
          <volume>359</volume>
          <year>2006</year>
          <fpage>285</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">17069746</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by <funding-source id="GS1">The
               Wellcome Trust</funding-source>, the <funding-source id="GS2">Scottish Universities Life Science Alliance (SULSA)</funding-source> and the
               <funding-source id="GS3">BBSRC</funding-source>.</p>
    </ack>
    <fn-group>
      <fn id="fn1">
        <label>1</label>
        <p><italic>Abbreviations
                        used:</italic> hCypA, human cyclophilin-A; hPCNA, human proliferating
                     cell nuclear antigen; PPIase, peptidyl-prolyl isomerase; CsA, cyclosporin-A;
                     IEX, ion-exchange; GF,
                  gel-filtration.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig. 1</label>
      <caption>
        <p>Automated purification of hCypA. (A) SDS–polyacrylamide gel
               (4–20% gradient) illustrating the typical levels of soluble hCypA
               over-expressed from OverExpress C41 BL21(DE3) <italic>E. coli</italic> grown
               for 16 h at 37 °C in Overnight Express
               Instant TB Medium. hCypA makes up ∼6% of the total soluble protein.
                  <italic>T</italic><sub>o</sub>, soluble cell extract at mid log phase
               immediately after inoculation (<italic>A</italic><sub>600 nm</sub> ≈ 0.5);
                  <italic>T</italic><sub>16</sub>, soluble cell extract following
                  16 h of growth shaking (260 rpm) at 37 °C. (B) Typical chromatogram for the automated 2-step purification
               of hCypA using ÄKTAXpress™. The pre-packed columns used are illustrated
               above the corresponding section of the chromatogram; IEX – ion-exchange, GF
               – gel-filtration. Solid black; <italic>A</italic><sub>280 nm</sub> in mAU (left axis). Solid red; NaCl gradient in %
                  <italic>Buffer-B</italic> (right axis). The inset details the region of the
               gel-filtration column elution from which fractions were collected. Indicated
               fractions A7–B1 were pooled. (C) SDS–polyacrylamide gel (4–20%
               gradient) illustrating the final purity levels of hCypA purified by both traditional
               and automated protocols. Both methods produce protein of ⩾93% purity (determined
               by gel densitometry). Five μg total protein was loaded in each
               lane. Four independent traditional runs and 3 independent automatic runs are shown,
               illustrating the excellent reproducibility of both methods and the excellent
               comparable purity between the methods. Molecular weight markers are shown to the
               right of the gel. (D) Inhibition of the PPIase activity
                  (<italic>V</italic><sub>o</sub> in
                  μM<sup>−1</sup> s<sup>−1</sup>) of
               hCypA (15 nM) by cyclosporin (CsA). hCypA purified by either the
               traditional or automatic method shows the same high specific activity. Open
               triangles, black line, automatically purified hCypA; solid circles, red line,
               traditionally purified hCypA. The solid lines are a best fit to Eq. <xref rid="fd1" ref-type="disp-formula">(1)</xref> (see Materials and methods). The values for the
               equilibrium dissociation constant for cyclosporin inhibition
                  (<italic>K</italic><sub>i</sub>) are 24.3 ± 4.2 nM, for traditionally purified
               hCypA and, 19.7 ± 2.8 nM, for automatically purified hCypA, agreeing very well with literature values
                  <xref rid="bib42 bib44 bib48" ref-type="bibr">[42,44,48]</xref>. (For
               interpretation of the references to color in this figure legend, the reader is
               referred to the web version of this paper.)</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig. 2</label>
      <caption>
        <p>Automated Purification of hPCNA. (A) Typical chromatogram for the
               automated 4-step purification of hPCNA using ÄKTAXpress™. The pre-packed
               columns used are illustrated above the corresponding section of the chromatogram; IEX
               – ion-exchange, DS – desalt, AF – affinity, GF –
               gel-filtration. Solid black; <italic>A</italic><sub>280 nm</sub> in mAU (left axis). Solid red; elution gradient in %
                  <italic>Buffer-E</italic> or <italic>Buffer-G</italic> (right axis),
               IEX and AF step, respectively. The buffer pairs used are indicated above the
               appropriate portion of the chromatogram. The inset details the region of the
               gel-filtration column elution from which fractions were collected. Indicated
               fractions A7–C11 were pooled. (B) SDS–polyacrylamide gel (4–20%
               gradient) illustrating the final purity levels of hPCNA purified by both manual
               (⩾93%) and automated (⩾87%) protocols (determined by gel densitometry). The
               final purity from 2 independent traditional and 2 independent automatic runs are
               shown, illustrating the excellent reproducibility of both methods. Five μg total protein was loaded in each lane. SCE, soluble cell extract;
               R1, run 1; R2, run 2. Molecular weight markers are shown to the right of the gel.
               (For interpretation of the references to color in this figure legend, the reader is
               referred to the web version of this paper.)</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p>List of buffers, composition and recipes used for chromatography
               steps.</p>
      </caption>
      <table-wrap-foot>
        <fn id="tblfn1">
          <label>a</label>
          <p>Buffer recipe stock solutions and the ratio mixtures for the final buffer
               composition were generated as described in the UNICORN (v5.11, GE Healthcare)
               operating software.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <p>Purification of hPCNA and hCypA. Fractionation was performed on cell
               pellets obtained from 1 l of <italic>E. coli</italic>
               culture.</p>
      </caption>
      <table-wrap-foot>
        <fn id="tblfn2">
          <label>a</label>
          <p>Mean values from at least 2 individual repeat runs of the corresponding
               protocol. Protein concentration in the supernatant and the pooled fractions after
               each chromatographic step was determined by BCA protein assay, apart from the final
               S-200 pool where protein concentration was determined by
                  <italic>A</italic><sub>280</sub> measurements.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn3">
          <label>b</label>
          <p>Determined by densitometry of appropriate lanes on reducing
               SDS–polyacrylamide gels (4–20% gradient).</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>